[go: up one dir, main page]

MA56547A - Formulations d'agents pénétrants transdermiques contenant du cannabidiol - Google Patents

Formulations d'agents pénétrants transdermiques contenant du cannabidiol

Info

Publication number
MA56547A
MA56547A MA056547A MA56547A MA56547A MA 56547 A MA56547 A MA 56547A MA 056547 A MA056547 A MA 056547A MA 56547 A MA56547 A MA 56547A MA 56547 A MA56547 A MA 56547A
Authority
MA
Morocco
Prior art keywords
formulations containing
penetrating agent
agent formulations
containing cannabidiol
transdermal penetrating
Prior art date
Application number
MA056547A
Other languages
English (en)
Inventor
Ryan Beal
Nathan Fitzsimmons
Kilmar Martinez
Audrene Mcmahon
Brandon Sand
Original Assignee
Dyve Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyve Biosciences Inc filed Critical Dyve Biosciences Inc
Publication of MA56547A publication Critical patent/MA56547A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA056547A 2019-06-18 2020-06-18 Formulations d'agents pénétrants transdermiques contenant du cannabidiol MA56547A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863236P 2019-06-18 2019-06-18
US16/546,270 US11026896B2 (en) 2019-06-18 2019-08-20 Transdermal penetrant formulations containing cannabidiol
US16/546,269 US10842758B1 (en) 2019-06-18 2019-08-20 Transdermal penetrant formulations containing cannabidiol

Publications (1)

Publication Number Publication Date
MA56547A true MA56547A (fr) 2022-04-27

Family

ID=73461997

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056547A MA56547A (fr) 2019-06-18 2020-06-18 Formulations d'agents pénétrants transdermiques contenant du cannabidiol

Country Status (9)

Country Link
US (3) US11026896B2 (fr)
EP (1) EP3986385A1 (fr)
JP (1) JP2022537763A (fr)
KR (1) KR20220052903A (fr)
CN (1) CN115379833A (fr)
CA (1) CA3144261A1 (fr)
IL (1) IL289052A (fr)
MA (1) MA56547A (fr)
WO (1) WO2020257538A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4041209A4 (fr) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. Compositions transdermiques comprenant du cannabidiol (cbd) destinées à être utilisées dans le traitement de troubles épileptiques
CA3155181A1 (fr) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Administration transdermique de cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US20220047525A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
US12109381B2 (en) * 2020-08-26 2024-10-08 Babak Ghalili Cannabinoid and menthol transdermal delivery systems and methods
WO2022155352A1 (fr) * 2021-01-13 2022-07-21 Dyve Biosciences, Inc. Formulations d'agents pénétrants transdermiques pour l'administration de médicaments
WO2022187295A1 (fr) * 2021-03-02 2022-09-09 Acid Neutral Alkaline Laboratory Compositions de poloxamère et boissons
WO2022217147A1 (fr) * 2021-04-09 2022-10-13 Rosenfeld Mark J Procédés d'amélioration de la perméation cutanée de cannabinoïdes et d'amides d'acides gras
WO2023012691A1 (fr) * 2021-08-03 2023-02-09 Pike Therapeutics, Inc. Administration posologique transdermique d'agents pharmaceutiques
CN116159045B (zh) * 2021-11-24 2024-03-19 四川大学华西医院 大麻二酚和/或次大麻二酚在制备局部麻醉药药效增强剂中的应用
KR20240079179A (ko) 2022-11-28 2024-06-04 아이큐어 주식회사 칸나비디올을 유효성분으로 포함하는 경피흡수 패치제
US20240299501A1 (en) * 2023-03-06 2024-09-12 Xygenyx Inc. Composition and methods of treatment using transdermal hormone supplementation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
WO2008100977A2 (fr) * 2007-02-14 2008-08-21 N.V. Organon Agents de libération thérapeutiques
KR101833959B1 (ko) * 2009-10-23 2018-03-02 다우 코닝 도레이 캄파니 리미티드 오일-기반 원료 물질을 위한 증점제 또는 겔화제
US10028904B2 (en) * 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
WO2016105499A1 (fr) * 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Méthodes et formulations pour l'administration transdermique
US10028919B2 (en) * 2015-03-10 2018-07-24 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
US20160312252A1 (en) * 2015-04-24 2016-10-27 BiOWiSH Technologies, Inc. Compositions and methods for biodiesel production from waste triglycerides
CN108697803A (zh) * 2015-10-29 2018-10-23 索卢贝斯特有限公司 透粘膜给药的药物组合物
EP3435978A4 (fr) * 2016-03-31 2019-12-11 Smartech Topical, Inc. Système d'administration
EP3681494A4 (fr) * 2017-09-15 2021-08-04 Ampersand Biopharmaceuticals, Inc. Inhibition des métastases spontanées par des inhibiteurs protéiques des cystéine protéases
US20190177674A1 (en) * 2017-12-11 2019-06-13 CBD Spirits, LLC Systems, methods, and compositions of blended cannabinoid enriched beverages

Also Published As

Publication number Publication date
IL289052A (en) 2022-02-01
WO2020257538A1 (fr) 2020-12-24
JP2022537763A (ja) 2022-08-29
EP3986385A1 (fr) 2022-04-27
US20230038462A1 (en) 2023-02-09
US10842758B1 (en) 2020-11-24
CA3144261A1 (fr) 2020-12-24
CN115379833A (zh) 2022-11-22
US20200397716A1 (en) 2020-12-24
US11026896B2 (en) 2021-06-08
KR20220052903A (ko) 2022-04-28

Similar Documents

Publication Publication Date Title
MA56547A (fr) Formulations d'agents pénétrants transdermiques contenant du cannabidiol
EP4277616A4 (fr) Formulations d'agents pénétrants transdermiques pour l'administration de médicaments
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
MA45290A (fr) Procédés et compositions d'agents biologiquement actifs
MA41818A (fr) Timbre à micro-aiguilles pour administration d'un principe actif à la peau
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
PL417066A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
BR112018010234A2 (pt) spray formador de película tópica
EP2174667A4 (fr) Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
EP3412344A4 (fr) Composition d'agent extincteur
MA49116A (fr) Compositions pharmaceutiques contenant de l'insuline
EP3400218A4 (fr) Combinaison d'un composé de chromène et d'un second agent actif
AR110250A1 (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
EP4076382C0 (fr) Système thérapeutique transdermique contenant de l'agomélatine
PA8720601A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos
EP3416626A4 (fr) Microsphères contenant des agents thérapeutiques et méthodes d'utilisation associées
DOP2019000071A (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
EP3624779A4 (fr) Compositions pharmaceutiques à libération modifiée d'huperzine et leurs méthodes d'utilisation
EP3900711C0 (fr) Préparation d'absorption transdermique contenant du donépézil stabilisé
EP3572407A4 (fr) Dérivé d'isoxazolin-5-one et herbicide le contenant en tant que principe actif
EP3845251A4 (fr) Lieur contenant un arylnitro, conjugué anticorps-médicament contenant un lieur et utilisation d'un lieur
MA52587A (fr) Composés d'azabenzimidazole et produit pharmaceutique
MA50798A (fr) Procédés d'utilisation et compositions contenant du dulaglutide